Recro Pharma, Inc. Logo

Recro Pharma, Inc.

REPH

(1.0)
Stock Price

2,09 USD

-12.05% ROA

-22.81% ROE

-14993.9x PER

Market Cap.

177.424.698,00 USD

71.62% DER

0% Yield

-14.03% NPM

Recro Pharma, Inc. Stock Analysis

Recro Pharma, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Recro Pharma, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (24%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

3 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-57.89%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-25.69%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3166.2x) suggests it's overvalued, potentially making it an expensive investment.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-4) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Recro Pharma, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Recro Pharma, Inc. Technical Stock Analysis
# Analysis Recommendation

Recro Pharma, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Recro Pharma, Inc. Revenue
Year Revenue Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 51.952.000 100%
2016 69.337.000 25.07%
2017 71.834.000 3.48%
2018 77.347.000 7.13%
2019 99.219.000 22.04%
2020 66.499.000 -49.2%
2021 75.360.000 11.76%
2022 90.214.000 16.47%
2023 110.876.000 18.64%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Recro Pharma, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2011 1.828.301
2012 541.951 -237.36%
2013 543.632 0.31%
2014 7.874.187 93.1%
2015 12.281.000 35.88%
2016 33.278.000 63.1%
2017 33.095.000 -0.55%
2018 39.985.000 17.23%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Recro Pharma, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 485.257
2012 339.255 -43.04%
2013 546.119 37.88%
2014 3.997.596 86.34%
2015 13.017.000 69.29%
2016 12.742.000 -2.16%
2017 25.426.000 49.89%
2018 36.879.000 31.06%
2019 0 0%
2020 19 100%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Recro Pharma, Inc. EBITDA
Year EBITDA Growth
2011 -2.311.318
2012 -794.233 -191.01%
2013 -1.088.262 27.02%
2014 -11.861.239 90.83%
2015 -954.000 -1143.32%
2016 -18.148.000 94.74%
2017 -32.479.000 44.12%
2018 -45.681.000 28.9%
2019 9.576.000 577.04%
2020 205.000 -4571.22%
2021 11.332.000 98.19%
2022 279.000 -3961.65%
2023 -30.080.000 100.93%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Recro Pharma, Inc. Gross Profit
Year Gross Profit Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 23.898.000 100%
2016 32.185.000 25.75%
2017 33.641.000 4.33%
2018 34.187.000 1.6%
2019 48.238.000 29.13%
2020 12.365.000 -290.12%
2021 19.823.000 37.62%
2022 23.138.000 14.33%
2023 30.792.000 24.86%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Recro Pharma, Inc. Net Profit
Year Net Profit Growth
2011 -2.870.918
2012 -1.536.536 -86.84%
2013 -1.957.818 21.52%
2014 -16.134.158 87.87%
2015 3.033.000 631.95%
2016 -30.205.000 110.04%
2017 -50.080.000 39.69%
2018 -79.723.000 37.18%
2019 -18.630.000 -327.93%
2020 -27.501.000 32.26%
2021 -26.504.000 -3.76%
2022 -19.881.000 -33.31%
2023 -3.144.000 -532.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Recro Pharma, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 -1
2012 0 0%
2013 -1 0%
2014 -3 100%
2015 0 0%
2016 -3 100%
2017 -3 0%
2018 -4 33.33%
2019 -1 0%
2020 -1 100%
2021 -1 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Recro Pharma, Inc. Free Cashflow
Year Free Cashflow Growth
2011 -2.172.283
2012 -1.224.850 -77.35%
2013 -816.625 -49.99%
2014 -10.866.217 92.48%
2015 6.047.000 279.7%
2016 -6.972.000 186.73%
2017 -23.733.000 70.62%
2018 -53.723.000 55.82%
2019 -33.839.000 -58.76%
2020 464.000 7392.89%
2021 5.569.000 91.67%
2022 -11.995.000 146.43%
2023 -2.271.000 -428.18%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Recro Pharma, Inc. Operating Cashflow
Year Operating Cashflow Growth
2011 -2.172.283
2012 -1.224.850 -77.35%
2013 -816.625 -49.99%
2014 -10.866.217 92.48%
2015 8.458.000 228.47%
2016 -3.202.000 364.15%
2017 -17.042.000 81.21%
2018 -43.115.000 60.47%
2019 -25.497.000 -69.1%
2020 8.067.000 416.07%
2021 10.858.000 25.7%
2022 -3.644.000 397.97%
2023 -146.000 -2395.89%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Recro Pharma, Inc. Capital Expenditure
Year Capital Expenditure Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 2.411.000 100%
2016 3.770.000 36.05%
2017 6.691.000 43.66%
2018 10.608.000 36.92%
2019 8.342.000 -27.16%
2020 7.603.000 -9.72%
2021 5.289.000 -43.75%
2022 8.351.000 36.67%
2023 2.125.000 -292.99%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Recro Pharma, Inc. Equity
Year Equity Growth
2011 -13.611.633
2012 -15.561.877 12.53%
2013 2.336 666276.24%
2014 18.928.589 99.99%
2015 40.350.000 53.09%
2016 71.613.000 43.66%
2017 28.848.000 -148.24%
2018 -19.500.000 247.94%
2019 -6.712.000 -190.52%
2020 -14.100.000 52.4%
2021 42.064.000 133.52%
2022 59.859.000 29.73%
2023 58.663.000 -2.04%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Recro Pharma, Inc. Assets
Year Assets Growth
2011 25.698
2012 154.072 83.32%
2013 1.026.112 84.98%
2014 20.373.620 94.96%
2015 138.697.000 85.31%
2016 182.997.000 24.21%
2017 186.226.000 1.73%
2018 155.493.000 -19.76%
2019 110.459.000 -40.77%
2020 103.415.000 -6.81%
2021 160.317.000 35.49%
2022 157.443.000 -1.83%
2023 153.474.000 -2.59%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Recro Pharma, Inc. Liabilities
Year Liabilities Growth
2011 13.637.331
2012 15.715.949 13.23%
2013 1.023.776 -1435.1%
2014 1.445.031 29.15%
2015 98.347.000 98.53%
2016 111.384.000 11.7%
2017 157.378.000 29.23%
2018 174.993.000 10.07%
2019 117.171.000 -49.35%
2020 117.515.000 0.29%
2021 118.253.000 0.62%
2022 97.584.000 -21.18%
2023 94.811.000 -2.92%

Recro Pharma, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-14993.9x
Price To Sales Ratio
1.87x
POCF Ratio
-198038.82
PFCF Ratio
-19.2
Price to Book Ratio
3392.75
EV to Sales
2.23
EV Over EBITDA
-16.46
EV to Operating CashFlow
-210.29
EV to FreeCashFlow
-22.87
Earnings Yield
-0
FreeCashFlow Yield
-0.05
Market Cap
0,18 Bil.
Enterprise Value
0,21 Bil.
Graham Number
0
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.08
ROE
-0.23
Return On Assets
-0.09
Return On Capital Employed
-0.03
Net Income per EBT
1.01
EBT Per Ebit
3.68
Ebit per Revenue
-0.04
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.19
Operating Profit Margin
-0.04
Pretax Profit Margin
-0.14
Net Profit Margin
-0.14

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
8.2
Capex to Revenue
-0.09
Capex to Depreciation
-0.92
Return on Invested Capital
-0.04
Return on Tangible Assets
-0.12
Days Sales Outstanding
63.93
Days Payables Outstanding
6.26
Days of Inventory on Hand
48.96
Receivables Turnover
5.71
Payables Turnover
58.31
Inventory Turnover
7.45
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.72
Debt to Assets
0.27
Net Debt to EBITDA
-2.64
Current Ratio
1.07
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
-0,04 Bil.
Invested Capital
0.72
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.28
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
11270500
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Recro Pharma, Inc. Dividends
Year Dividends Growth

Recro Pharma, Inc. Profile

About Recro Pharma, Inc.

Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.

CEO
Ms. Geraldine Henwood
Employee
185
Address
490 Lapp Rd
Malvern, 19341

Recro Pharma, Inc. Executives & BODs

Recro Pharma, Inc. Executives & BODs
# Name Age

Recro Pharma, Inc. Competitors